← FDA DRUG APPROVALS

FDA ANDA · ANDA091225

CLINDAMYCIN HYDROCHLORIDE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA091225
TYPE
ANDA
ORIGINAL APPROVAL
2011-05-31
LATEST ACTION
2025-05-23
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CLINDAMYCIN HYDROCHLORIDEDiscontinued
CLINDAMYCIN HYDROCHLORIDE EQ 150MG BASE · CAPSULE · ORAL
CLINDAMYCIN HYDROCHLORIDEDiscontinued
CLINDAMYCIN HYDROCHLORIDE EQ 300MG BASE · CAPSULE · ORAL
CLINDAMYCIN HYDROCHLORIDEDiscontinued
CLINDAMYCIN HYDROCHLORIDE EQ 75MG BASE · CAPSULE · ORAL

Approval history

2025-05-23Labeling · Supplement 8 · standardAP
2023-09-14Labeling · Supplement 6 · standardAP
2023-09-14Labeling · Supplement 4 · standardAP
2023-09-14Labeling · Supplement 2 · standardAP
2023-09-14Labeling · Supplement 7 · standardAP
2023-09-14Labeling · Supplement 5 · standardAP
2023-09-14Labeling · Supplement 3 · standardAP
2013-03-11Labeling · Supplement 1 · standardAP
2011-05-31OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →